Concepedia

Multicenter phase II–III study of oxaliplatin plus cyclophosphamide vs. cisplatin plus cyclophosphamide in chemonaive advanced ovarian cancer patients

J.L. Misset, P Vennin, P. Chollet, P Pouillart, P. Laplaige, J.L. Frobert, D. Castéra, M. Fabro, Denis Langlois, Enrico Cortesi,

Annals of Oncology · 2001 · 35 citations · 15 references

DOIFull text

Open access

Concepts

References

15

Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer

William P. McGuire, William J. Hoskins, Mark F. Brady et al. · New England Journal of Medicine · 1996 · 2.9K citations · Full text

, , +16

Phase III Randomized Study of Cisplatin Versus Paclitaxel Versus Cisplatin and Paclitaxel in Patients With Suboptimal Stage III or IV Ovarian Cancer: A Gynecologic Oncology Group Study

Franco M. Muggia, Patricia S. Braly, Mark F. Brady et al. · Journal of Clinical Oncology · 2000 · 619 citations

, , +17

Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the national cancer institute's anticancer drug screen panel

Olivier Rixe, Waldo Ortuzar, Manuel Álvarez et al. · Biochemical Pharmacology · 1996 · 615 citations

, , +15

Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer.

Graham J. Kemp, Peter S. Rose, John R. Lurain et al. · Journal of Clinical Oncology · 1996 · 469 citations

, , +17

In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair.

Daniel Fink, Hongtu Zheng, S Nebel et al. · PubMed · 1997 · 278 citations

, , +17